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ABSTRACT
Background Selenium (Se), an essential trace mineral, 
has been implicated in preterm birth (PTB). We aimed to 
determine the association of maternal Se concentrations 
during pregnancy with PTB risk and gestational duration 
in a large number of samples collected from diverse 
populations.
Methods Gestational duration data and maternal 
plasma or serum samples of 9946 singleton live births 
were obtained from 17 geographically diverse study 
cohorts. Maternal Se concentrations were determined by 
inductively coupled plasma mass spectrometry analysis. 
The associations between maternal Se with PTB and 
gestational duration were analysed using logistic and linear 
regressions. The results were then combined using fixed- 
effect and random- effect meta- analysis.
Findings In all study samples, the Se concentrations 
followed a normal distribution with a mean of 93.8 ng/mL 
(SD: 28.5 ng/mL) but varied substantially across different 
sites. The fixed- effect meta- analysis across the 17 cohorts 
showed that Se was significantly associated with PTB 
and gestational duration with effect size estimates of an 
OR=0.95 (95% CI: 0.9 to 1.00) for PTB and 0.66 days (95% 
CI: 0.38 to 0.94) longer gestation per 15 ng/mL increase 
in Se concentration. However, there was a substantial 
heterogeneity among study cohorts and the random- effect 
meta- analysis did not achieve statistical significance. 
The largest effect sizes were observed in UK (Liverpool) 
cohort, and most significant associations were observed in 
samples from Malawi.
Interpretation While our study observed statistically 
significant associations between maternal Se 
concentration and PTB at some sites, this did not 
Key questions
What is already known?
 ► Conflicting results have been reported on the asso-
ciation between maternal selenium (Se) levels and 
preterm birth (PTB) risk.
 ► Most previous studies were typically small or fo-
cused on a single geographic region with limited 
data in populations at high risk for PTB.
What are the new findings?
 ► Maternal prenatal plasma/serum Se concentrations 
varied substantially between different geographic 
regions.Clinically meaningful associations were ob-
served between maternal Se concentration and PTB 
within specific cohorts; however, this finding was not 
generalisable across all the cohorts.
 ► The significant associations observed in specific 
study cohorts might be mediated or confounded by 
individual site- specific factors.
What do the new findings imply?
 ► Our results do not support a uniform association be-
tween maternal prenatal Se concentration and PTB 
risk.
 ► The significant associations observed in specific 
study cohorts might have potential implications for 
targeted Se supplementation in hig- risk settings.
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generalise across the entire cohort. Whether population- specific factors 
explain the heterogeneity of our findings warrants further investigation. 
Further evidence is needed to understand the biologic pathways, 
clinical efficacy and safety, before changes to antenatal nutritional 
recommendations for Se supplementation are considered.
INTRODUCTION
Preterm birth (PTB), defined as delivery prior to 37 
completed weeks of gestation, is the leading global cause 
of infant and under-5- year old childhood mortality.1 Each 
year, an estimated 15 million babies are born preterm, 
of whom approximately 1 million die with complications 
of prematurity.2 Most countries with reliable trend data 
show an increase in PTB rates over the past 20 years, with 
more than 60% of cases occurring in Africa and South 
Asia.2–4 Due to the immaturity of multiple organ systems, 
preterm infants are at increased risk of short- term and 
long- term health sequelae including cognitive disabili-
ties, impaired motor skills, hearing loss, chronic immu-
nologic/infectious morbidities5 6 and elevated risks of 
adulthood obesity, diabetes and hypertension.7–9
Despite the profound global health significance and 
recognition that the prevention of PTB would provide 
major improvements in child health, there has only been 
limited progress in preventing PTB. Recently, a two- stage 
genome- wide association study of over 50 000 women of 
European ancestry identified and replicated EEFSEC 
gene, encoding the selenocysteine tRNA (tRNASeleno)- 
specific eukaryotic elongation factor, that was robustly 
associated with gestational duration.10 EEFSEC plays a 
critical role in incorporating selenium (Se) in the form 
of selenocysteine into selenoproteins such as glutathione 
peroxidases, the iodothyronine 5′-deiodonases, seleno-
protein P and thioredoxin reductases.11 The implication 
of selenocysteine pathway suggests a potential benefit 
for further evaluation of the role of maternal Se status 
on PTB risk. The possible involvement of maternal Se 
concentration in PTB has also been suggested by previous 
epidemiological studies;12–16 however, the sample sizes 
of these studies were usually small, or focus on a single 
geographic area and the results are not always consistent 
between studies.17 18
In this study, we aimed to examine the association 
of maternal Se concentrations during pregnancy with 
PTB risk and gestational duration. As dietary Se intake 
is highly related to its regional soil content,19 we lever-
aged the availability of archived biological samples from 
geographically diverse cohorts and tested the association 
between maternal Se concentrations and gestational 
duration in a large number of samples collected from 
these study cohorts with different social and ancestral 
background and varying degrees of Se exposures.
METHODS
Study design and participants
The International Consortium on Selenium, Genetics, 
and Preterm Birth is a Bill & Melinda Gates Foundation 
(BMGF) funded project to study the potential association 
between maternal Se concentration and PTB risk using 
existing samples and data from multiple birth studies. 
The consortium comprises 17 international pregnancy 
cohorts across a wide geographic distribution (figure 1) 
with Cincinnati Children’s Hospital Medical Center 
(CCHMC) serving as the coordinating hub. Among the 
Figure 1 Geographic location of study sites.
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participating sites, Malawi (iLiNS- DYAD)20 and Bang-
ladesh (MDIG)21 cohorts were intervention trials and 
USA, CA (CPPOP) was a case–control study. All the 
other cohorts were designed to enrol women randomly 
at hospitals. Description and study characteristics of 
these participating study cohorts are provided in online 
supplemental text 1 and online supplemental table 1).
Samples and sampling data
Demographic, prenatal, delivery and fetal/newborn 
data (online supplemental table 2) as collected by the 
individual sites according to their local protocols were 
shared with the coordinating hub (CCHMC). The 
data collected from Bangladesh (GAPPS), Bangladesh 
(MDIG),21 Vietnam (PBB), USA (NEST; CPPOP),22 23 
and all AMANHI cohorts24 were case/control (preterm/
term) samples. The data collected from other sites 
including Malawi (iLiNS- DYAD),20 Zambia (GAPPS) 
and the six INTERBIO sites25 were random samples with 
a PTB rate ranging from 4.5% (INTERBIO, Kenya) to 
20% (INTERBIO, Pakistan). Gestational age dating was 
assigned at the site level by ultrasound, last menstrual 
period (LMP) or both (online supplemental table 1). 
Preterm cases were defined as birth prior to 37 weeks of 
gestation and term controls as birth at 37 weeks or later. 
We excluded stillbirths and multigestational pregnancies.
Selenium measurement
Se status was assessed on the basis of the concentrations 
of Se in plasma or serum.26 Plasma or serum samples 
obtained from participating cohorts were stored at 
−70°C or −80°C refrigerators before and after use at the 
CCHMC Biobank (online supplemental table 1). To 
mitigate potential batch effect, samples from each site 
were randomised prior to analysis in batches. Induc-
tively coupled plasma mass spectrometry (ICP- MS) 
measurements of Se concentrations in serum or plasma 
were performed using Agilent 7700 ICP- MS (Agilent 
Technologies) at the laboratory of Clinical Chemistry 
and Biochemistry, University of Cincinnati as described 
in detail in the protocol (online supplemental text 2) 
except the samples from Bangladesh (MDIG) which were 
analysed at the Centers for Disease Control and Preven-
tion (Atlanta, GA).
Statistical analysis
Phenotypic data from participating study sites were harmo-
nised by applying a uniform data structure and consistent 
coding rules for phenotype variables (eg, gestational dura-
tion, maternal age, height and fetal sex). Maternal Se data 
generated by the laboratory were combined and merged 
with phenotype data. The distributions of gestational dura-
tion and Se measures for each site were visually inspected 
using histograms and violin plots. Outliers for gestational 
duration and Se measurements were detected based on 
fitting with appropriate probability distributions and 
removed from further association analysis.
To determine the covariates to be included in the asso-
ciation analysis, we first examined the correlation of PTB 
(and gestational duration) with other covariates as well 
as the correlation between Se concentration and other 
covariates in each site using Pearson correlation. Vari-
ables significantly correlated (p<0·05) with either PTB or 
gestational duration or Se concentration were included 
as covariates. The DerSimonian- Laird (DSL) random- 
effect meta- analysis was used to combine the correlation 
coefficients obtained from each cohort. For each site, we 
estimated the association between maternal Se concentra-
tion and PTB (and gestational duration as a continuous 
variable) using logistic (for PTB) or linear (for gestational 
duration) regression analysis. Fixed- effect meta- analysis 
and random- effect meta- analysis were used to combine 
the results from different cohorts. Between- study hetero-
geneity was checked using Cochran’s Q test. Some of 
the cohorts used case/control samples (online supple-
mental table 1) and regression analysis of gestational 
duration as a continuous variable without accounting for 
the non- random sampling could potentially introduce 
bias in effect size estimation. To address this problem, 
we conducted regression analysis weighted by inverse of 
sampling probability (IPW). Detailed description of this 
analysis can be found in online supplemental text. All 
analyses were done with Microsoft R Open 3.5.1.
Patient and public involvement
Patients or public were not involved in setting the research 
question or the outcome measures, nor were they involved 
in the design or conduct of the study. No participants 
were asked to advise on interpretation or writing up of the 
manuscript. For the study, individual study cohorts shared 
the archived biological samples from established biobanks 
and there is no direct patient or public involvement.
RESULTS
Gestational duration, PTB and their correlations with other 
covariates
Pregnancy phenotype and birth outcomes of 10 640 preg-
nancies were obtained from 17 study sites (online supple-
mental table 1). Among these, 9946 singleton livebirths 
had gestational duration measured in days (gday) and 
maternal plasma or serum samples (figure 2). The demo-
graphic characteristics of these mothers (eg, age and 
height) and the major birth outcomes (eg, gestational 
duration and birth weight) are summarised by the site 
(table 1). After removing three outliers, the gestational 
duration followed a Weibull distribution with a mean of 
268 days and ranging from 147 to 312 days (distribution 
parameters: shape: 21.2, scale: 275.8) (online supple-
mental figure 1). The distributions of gestational days 
in term (gday ≥259 days) and preterm (gday <259 days) 
deliveries from each site are shown in online supple-
mental figure 2.
We examined the correlation of PTB and gestational 
duration with other covariates (maternal age, height, fetal 
sex and gestational age at sampling) in each participant 
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site (online supplemental figure 3). Meta- analysis using 
DSL method showed that PTB risk was significantly 
associated with maternal height and fetal sex. Similarly, 
gestational duration was also significantly associated with 
maternal height (shorter mothers had shorter gesta-
tional duration) and fetal sex (males had shorter gesta-
tional duration).
Maternal prenatal Se concentration and its correlations with 
other covariates
Se concentrations were successfully measured in 9944 
mothers. After removing two outliers, the Se concentra-
tions followed a normal distribution with some positive 
skewness (online supplemental figure 4) with a mean 
of 93.8 ng/mL and SD of 28.5 ng/mL. Se levels varied 
substantially across different sites (figure 3, online 
supplemental figure 5), and also across different experi-
mental batches for each site (online supplemental figure 
6). The highest average Se was observed in the Tanzania 
(AMANHI) cohort with a mean level of 131.4 ng/mL, 
and the lowest Se was observed in Zambia (GAPPS)with a 
mean concentration of 55.9 ng/mL. The largest variation 
was observed in Malawi (iLiNS- DYAD) (range: 26.1 to 
228.7 ng/mL, SD=29.5) (online supplemental table 3).
We examined the correlation of maternal Se concen-
tration with other covariates in each site. When 
combined across sites, the Se concentration across sites 
was significantly positively correlated with maternal age 
(ρ=0·08, p=2.5e−5) and negatively correlated with gesta-
tional age at the time of sample collection (ρ = −0.13, 
p=3.0e−5) (online supplemental figure 7). The gesta-
tional age at sample collection varied substantially from 
site to site and in some sites, there were some samples 
collected after second trimester (≥28 weeks). In order 
to minimise the bias introduced by these samples (eg, 
exclusion of extremely PTB and reduction of maternal 
Se concentration), we excluded 416 samples which were 
collected at 28 weeks of gestational age or later and four 
samples without known date of sample collection) from 
the final association analysis (online supplemental figure 
8).
Association of maternal selenium concentration with PTB and 
gestational duration
We examined the association of maternal prenatal Se 
(before third trimester with gestational duration at sample 
collection <28 weeks) with PTB and gestational duration 
in each individual site and then combined the results 
using meta- analysis (figure 4). In total, the associations 
were tested in 9519 pregnancies (figure 2). The following 
factors found to be significantly associated (p<0.05) with 
either gestational duration or Se concentration were 
incorporated as covariates. These include maternal 
age (mage), maternal height (ht), fetal sex (fsex) and 
Figure 2 Flow chart of the study illustrating the total number of subjects, inclusion/exclusion criteria.
copyright.
 on O












ealth: first published as 10.1136/bm















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ealth: first published as 10.1136/bm






6 Monangi N, et al. BMJ Global Health 2021;6:e005856. doi:10.1136/bmjgh-2021-005856
BMJ Global Health
gestational days at sample collection (gday(sample)) and 
experimental batch (batch).
The fixed- effect meta- analysis across the 17 cohorts 
showed that Se concentration was significantly associated 
with PTB and gestational duration. The associated effect 
size estimates were an OR=0.95 (95% CI: 0.9 to 1.00) for 
PTB or 0.66 days (95% CI: 0.38 to 0.94) longer gestation 
per 15 ng/mL increase in Se concentration. However, 
there was substantial between cohort heterogeneity 
as shown by the forest plots (figure 4) and the signifi-
cant p values for Cochran’s Q statistic (p=0.0037 for 
PTB and p=6.03e−5 for gestational duration). Given the 
enrichment of preterm cases in the case–control studies 
that could potentially introduce bias, we conducted the 
IPW analysis in the eight case/control data sets and the 
results were similar to the meta- analysis of gestational age 
without adjustments (online supplemental figure 9).
The largest effect sizes were observed in UK (Liver-
pool) cohort, and highly significant associations were 
observed in Malawi (iLiNS- DYAD) samples (figure 4). 
Other than these two, only the Tanzania (AMANHI) 
cohort showed associations with marginally smaller 
p- values (PTB: p=0.026 and gestational duration: 
p=0.049). After excluding the Malawi (iLiNS- DYAD) and 
Figure 3 Selenium concentration by participating sites.
Figure 4 Meta- analysis of the association of maternal Se concentration with PTB (A) and gestational duration (B). (A) The 
estimated association between Se concentration and PTB is shown as OR per 15 ng/mL increase in Se concentration. (B) The 
estimated association between Se concentration and gestational duration is shown as change in gestational days per 15 ng/
mL increase in Se concentration. PTB, preterm birth; Se, selenium.
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UK (Liverpool) cohorts, the fixed- effect meta- analysis 
was no longer significant (PTB: p=0.82 and gestational 
duration: p=0.92). Given the large between study hetero-
geneity, we also conducted a random- effect meta- analysis 
of all 17 cohorts. The associations of maternal Se concen-
trations with PTB and gestational duration in this model 
did not achieve statistical significance (PTB: p=0.081 and 
gestational duration: p=0.24).
Stratified analysis of Malawi cohort
As noted above, the Malawi (iLiNS- DYAD) cohort 
showed the most significant associations between Se 
concentrations and PTB (p=0.00062) and gestational 
duration (p=7.7e−9) (figure 4). Given these findings, 
we attempted to investigate possible factors that drove 
these associations. Participants of the Malawi cohort were 
enrolled from four health facilities that covered mostly 
one continuous area near Lake Malawi (figure 5A). 
Lungwena, Malindi and Mangochi subsites are along 
the banks of Lake Malawi and close to Namizimu forest 
reserve. The Namwera subsite is in the mountains and 
relatively distant from the other three sites. The demo-
graphic characteristics of the mothers (eg, age and 
height) and the major birth outcomes (eg, gestational 
duration and birth weight) separated by geographic 
distribution were summarised by the subsites (online 
supplemental table 4). Compared with the other sites, 
participants from Namwera had a higher PTB rate (14%) 
and lower mean gestational duration and birth weight 
(figure 5B and online supplemental table 4). The lowest 
mean Se (mean=56.8 ng/mL and SD=14.4 ng/mL) was 
also observed in Namwera samples (figure 5B and online 
supplemental table 5). When subsite of sample collection 
was included as a covariate the effect size estimations of 
maternal Se concentration were OR=0.85 (95% CI: 0.72 
to 1.00) for PTB and 0.49 longer days of gestation (95% 
CI: 0.07 to 0.92) per 15 ng/mL increase in Se concen-
tration (online supplemental figure 10). Although still 
significant, these estimates were smaller than the esti-
mates obtained without adjustment for subsites (OR=0.78 
(CI: 0.68 to 0.90) or 1.17 days (95% CI: 0.78 to 1.57)) 
(figure 4).
Stratified analysis of UK (Liverpool) cohort
The largest effect sizes for Se concentration on gesta-
tional duration (3.96 days longer gestation per 15 ng/
mL increase in Se) or PTB risk (OR=0.67 per 15 ng/mL 
increase in Se) were observed in the Liverpool cohort 
(figure 4). This cohort included 272 high- risk mothers 
who had a previous PTB and 253 low- risk mothers who 
did not have previous history of PTB. Among the 272 
high- risk mothers, 97 (36%) of them had a subsequent 
PTB (online supplemental table 6). The average Se 
concentration was lower in the high- risk mothers than 
the low- risk mothers (mean=77.6 vs 82.7, t- test p=0.0002) 
(figure 6A and online supplemental table 7). In both low- 
risk and high- risk groups, Se concentration was positively 
associated with gestational duration (1.93 days (95% CI: 
0.63 to 3.23) per 15 ng/mL increase in Se concentration 
(figure 6B)) and Se concentration was also associated 
with PTB risk in the high- risk group (OR=0.74 per 15 ng/
mL increase in Se concentration, CI: 0.56 to 0.98).
DISCUSSION
In this multicountry study conducted in low- resource 
Asian and African countries with high rates of PTB risk 
and high- resource European and US contexts, we studied 
the maternal prenatal Se concentrations and their asso-
ciation with the risk of PTB and gestational duration. 
We found that the Se concentrations varied substan-
tially across different study cohorts. The highest levels 
Figure 5 Geographic distribution of the four Malawi subsites (A) and distributions of gestational duration and maternal Se 
concentration at these four sample recruitment sites (B). PTB, preterm birth; Se, selenium.
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of maternal Se were observed in samples collected from 
Pemba Island (Tanzania) and in the USA (California 
(CPPOP) and North Carolina (NEST) cohorts. The 
lowest levels of maternal Se were observed in Zambia 
(GAPPS) and Brazil (INTERBIO). The average levels 
of maternal Se in the two cohorts with the lowest levels 
of maternal Se (<60 ng/mL) were less than half of the 
average levels observed in the cohorts with the highest 
levels of maternal Se (>125 ng/mL) (figure 3).
Possible explanation of our findings
Our result demonstrates the substantial variation in Se 
between different geographic regions. However, even 
among sites in geographic and cultural proximity (eg, the 
three Bangladesh or the two Pakistan sites), the maternal 
Se levels were still different, indicating factors other 
than geographic location likely influenced maternal Se 
levels. We also found that the Se concentration positively 
correlated with maternal age and negatively correlated 
with gestational age at the time of sample collection. It is 
unknown whether the decrease of maternal Se reflects the 
overall increased consumption of nutrients during preg-
nancy or if Se is utilised by specific biological processes in 
pregnancy. Also, it is unclear if the decrease in maternal 
Se with gestational age is due to relative haemodilution 
because of progressively greater expansion of plasma 
volume than the increase in red blood cell mass.
In the association analysis between maternal Se 
concentrations (before third trimester), PTB and gesta-
tional duration, we obtained heterogeneous results from 
the 17 cohorts (figure 4). We observed significant nega-
tive associations between maternal Se and PTB risk and 
positive associations with gestational duration in Malawi 
(iLiNS- DYAD), UK (Liverpool) and Tanzania (AMANHI) 
cohorts. However, the associations were not significant 
in other cohorts and the random- effect meta- analysis of 
the 17 cohorts altogether also did not show significant 
associations.
Further stratified analysis of the Malawi (iLiNS- DYAD) 
cohort based on the geographic locations of the four 
sample collection sites (within 30 km apart, figure 5A) 
suggested that the observed association between Se 
concentration with PTB and gestational duration was 
mainly driven by the Namwera site (figure 5B). This site 
had participants with the highest PTB rate and shortest 
gestational duration, and lowest Se concentration 
compared with other three sites near the coast of Lake 
Malawi. After adjustment for the site of sample collec-
tion, the estimated effect size and significance of the 
associations substantially attenuated. This result suggests 
that there may be some site- specific confounding factors. 
However, it is also possible that the low Se concentration is 
a driving factor that causes the high PTB rate and shorter 
gestational duration in the Namwera samples because in 
Namwera samples alone, Se concentration is significantly 
associated with PTB risk and gestational duration.
The association with the largest effect size between Se 
and gestational duration was observed in the UK (Liver-
pool) cohort which included a high- risk and a low- risk 
group of mothers based on their previous history of 
PTB. The Se concentration was significantly different 
between these two groups (figure 6A), which suggests 
the Se concentration might be an indicator of some long- 
term risk for PTB which may have also had an effect on 
previous pregnancies in this cohort. Within each of the 
UK (Liverpool) groups, maternal Se concentration was 
associated with the gestational duration of the current 
pregnancies (figure 6B). In another UK cohort (UK 
INTERBIO collected at Oxford), the mean Se concen-
tration was approximately 10 ng/mL higher but was 
not associated with PTB risk or gestational duration. 
Figure 6 Selenium concentrations of Liverpool cohort (A) and the meta- analysis of maternal Se concentration associated with 
gestational duration (B). Se, selenium.
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These disparate findings even between two UK cohorts 
suggests that unmeasured site- specific factors are either 
confounding or modifying the associations between 
maternal Se concentration and gestational duration.
Comparison with other studies
Our findings contribute to an emerging literature 
focused on the association of Se status and pregnancy 
outcomes, especially the risk for PTB or gestational dura-
tion. Evidence supporting the potential involvement of 
Se in PTB risk includes a study of Dutch women in which 
the lowest quartile of serum Se had twice the risk of PTB 
as women in the upper three quartiles.12 Another study 
of pregnant women with HIV in Lagos, Nigeria showed 
significant associations observed between maternal Se 
deficiency and PTB.13 The Norwegian Mother, Father and 
Child Cohort study showed that higher Se intake from 
food was associated with increase in gestational length 
and decreased PTB risk.15 Furthermore, the Maternal 
Health and Birth outcomes study in South East Queens-
land, Australia, suggested that dietary Se concentrations 
were significantly higher in women birthing beyond 41 
completed weeks of gestation in that cohort.14 However, 
there are also reports on Se metabolism with regard to 
gestational length that find contradicting results. The 
Japan Environment and Children’s Study (JECS) did 
not find an association between serum Se concentration 
and PTB risk.17 The Screening for Pregnancy Endpoints 
(SCOPE) study in Adelaide suggested that lower circu-
lating levels of Se may be associated with a reduced risk 
of pregnancy complications including PTB risk.16 Of 
note is the fact that these previous studies mostly focus 
on a single geographic region, have limited or no Se defi-
ciency and are generally based on small sample sizes.
Our study is the most extensive investigation of the 
association between mid- pregnancy Se concentration 
and the gestational duration and PTB in global popula-
tions, including several lower- income Asian and African 
countries with a very high baseline PTB risk. The diver-
sity of our study participants and the wide distribution 
of study sites across different geographic regions enable 
us to draw some general conclusions. Overall, our results 
do not support a ubiquitous and strong association 
between maternal Se concentration and PTB risk. The 
lack of significant associations in the cohorts with low 
average Se concentration also suggests Se deficiency is 
not the primary factor influencing PTB risk. The signif-
icant associations observed in some study cohorts might 
be confounded or mediated by site- specific factors. For 
example, Se concentration might be associated with 
certain dietary patterns or socioeconomic status that 
drive the PTB risk or certain local factors that might 
interact with Se and jointly influence PTB risk in some 
high- risk pregnancies.
Clinical importance
Several biologic mechanisms have been hypothesised to 
link Se status and PTB risk. Selenoproteins serve critical 
cellular homeostatic functions in maintaining redox 
status and antioxidant defenses, and modulate inflamma-
tory responses, which have been linked to PTB.27 In some 
instances, preterm parturition is thought to be prompted 
by a cascade of inflammatory events, leading to cytokine 
upregulation and subsequent induction of uterine activity 
by promoting the expression and release of uterotonic 
factors.28 The essential micronutrient Se, which exerts its 
antioxidant and anti- inflammatory properties in the form 
of selenoproteins such as glutathione peroxidase 3, sele-
noprotein P1 and thioredoxin reductase, has been shown 
to be protective in various inflammatory- based disease 
models.29–31 A recent study in mice showed that Se in the 
form of selenoproteins played an indispensable role in 
uterine smooth muscle contractions, and the absence 
of any of these proteins affected the uterine contrac-
tility.32 In vitro study of Se supplementation demon-
strated that selenite suppresses key mediators involved in 
inflammation- induced activation of mediators involved in 
active labour in human fetal membranes and the myome-
trium.33 Further investigations may benefit from looking 
in more detail at whether pregnancies exhibiting higher 
levels of inflammation or increased cytokine dysregula-
tion benefit from higher levels of Se in terms of increased 
gestational duration or decreased PTB risk.
The hierarchy of biological activities of Se calls for 
biomarkers informative at different levels of Se expo-
sure assessing Se intake, tissue Se, Se excretion and Se 
function.26 Plasma or serum Se level provides valuable 
information about the Se status over a wide range of Se 
intake; however, there is need for additional Se specia-
tion information particularly for assessing Se status in 
non- deficient individuals for whom there is high risk for 
PTB. Epidemiological reports and research examining 
the effects of different Se species and their bioavailability 
and bioactivity especially during pregnancy are lacking. 
There are recent reports suggesting that the non- linear 
associations between whole blood Se and plasma Se may 
be primarily due to accumulation of large proportion of 
selenoneine in red blood cells especially in coastal popu-
lations consuming marine foods.34
Strengths and limitations
There are some significant limitations of the current 
study. Of note is the fact that the samples and pheno-
typic data were retrieved from existing biorepositories 
collected several years ago in different studies. Although 
we harmonised and analysed a set of key variables known 
to be associated with PTB and gestational duration, we 
were not able to include some important environmental 
or socioeconomic factors in the analysis due to missing 
or incomplete data. We excluded stillbirth due to missing 
data on cause- of- death, under- reporting and lack of 
comparability in reporting of stillbirths, especially in 
low- income and middle- income countries regarding the 
birth weight and gestational age criteria. It will be key to 
include these variables across cohorts in future studies.
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There were differences in how gestational age was deter-
mined and distributed across cohorts. Some cohorts deter-
mined the duration by ultrasound whereas others used 
LMP (or both). This different dating methodology between 
studies may have introduced some noise into the analysis. 
PTB rates reported in some low- income and middle- income 
cohort studies appear to be low, and this might be due to 
under- reporting and geographic location of the recruitment 
site. Also, some cohorts were enriched for PTB samples, 
and the distribution of gestational duration did not follow 
a normal distribution. Although regression analysis is gener-
ally robust regardless of meeting the normality assumption, 
this difference may have introduced some bias in these anal-
yses. Also, we tested PTB as primary outcome using logistic 
regression, which is valid to both case–control and random 
samples. These issues certainly point to the importance of 
standardising dating and sampling methods as investigations 
move forward.
Also, of note with respect to the study limitations is that 
there was large variation in gestational age at when the 
plasma/serum samples were collected. Also, the samples 
were stored for different periods of time. Given the gesta-
tional age at sample collection significantly correlated 
with the Se concentration, we accounted for this vari-
ance by including only the pregnant mothers with 
samples collected before or during the second trimester 
and included gestational age at sample collection as a 
covariate in the final association analysis. Despite these 
methodological adaptations, it is possible that we may 
not have completely accounted for the influence of 
gestational age at sample collection if the effect is not 
completely linear. More standardisation with respect to 
timing of collection and storage times may simplify these 
types of analyses in future studies.
In addition, given that the major source of Se is food, 
and the large proportion of it comes from the staple food 
items such as rice, wheat and seafood,19 it is clear that 
studies looking at Se, PTB risk and gestational duration 
would benefit from more data on diet and nutrition. 
While information regarding the dietary intake of Se or 
other supplements during the pregnancy was not readily 
available for the majority of the enrolled subjects from 
the study sites, collection of such data in future studies 
would be hugely beneficial.
Finally, the generalisability of our results from the Se 
measurements to all study populations was likely limited 
due to the considerable variation in the local factors that 
influence the Se levels or modify the effect of Se during 
pregnancy. This highlights the need for larger coordinated 
studies examining extraneous factors that may be associated 
with Se levels, risk of PTB and gestational duration in preg-
nant women across different geographic settings.
CONCLUSIONS
We studied maternal prenatal Se concentration and tested 
whether it is associated with the risk of PTB and gesta-
tional duration using data and samples collected from 
17 international birth cohorts with diverse ethnic back-
ground and geographic distribution. Our study observed 
statistically significant associations between maternal Se 
concentration and PTB at some sites; however, this did 
not generalise across the entire cohort, which might 
lower the enthusiasm for wide use of Se supplements as 
a general strategy to prevent PTB or increase gestational 
duration. The significant associations observed in some 
cohorts and not others suggest local confounding factors 
or other risk modifiers. Effects of Se supplementation on 
PTB in high- risk populations with low Se in food (like 
Namwera region in Malawi) or in high- risk mothers with 
previous history of PTB need to be confirmed, ideally 
through a double- blind, placebo controlled clinical trial. 
Future studies that expand and refine sampling in popu-
lations that are found to have the greatest variations in Se 
intake and Se deficiency, along with Se speciation analysis 
will shed further light on the whether there is a potential 
relationship between Se, PTB risk and gestational dura-
tion.
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